Venoarterial extracorporeal membrane oxygenation for treatment of cardiogenic shock: Clinical experiences in 45 adult patients

Bakhtiary, Farhad; Keller, Harald; Doğan, Selami; Dzemali, Omer; Oezaslan, Feyzan; Meininger, Dirk; Ackermann, Hanns; Zwißler, Bernhard; Kleine, Peter; Moritz, Anton

doi:10.1016/j.jtcvs.2007.08.007

Cited by 182 publications

(137 citation statements)

References 13 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…Extracorporeal membrane oxygenation (ECMO) is increasingly used for treatment of patients with critical cardiopulmonary failure (1)(2)(3)(4). Recovery from ECMO largely depends on the underlining disease process since ECMO is only a supportive measure (4).…”

Section: Introductionmentioning

confidence: 99%

The Impact of Vascular Complications on Survival of Patients on Venoarterial Extracorporeal Membrane Oxygenation

Tanaka

Hirose

Cavarocchi

et al. 2016

The Annals of Thoracic Surgery

149

124

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

The Impact of Vascular Complications on Survival of Patients on Venoarterial Extracorporeal Membrane Oxygenation

Tanaka

Hirose

Cavarocchi

et al. 2016

The Annals of Thoracic Surgery

149

124

View full text Add to dashboard Cite

“…Timely initiation of mechanical circulatory support such as venoarterial extracorporeal membrane oxygenation (V-A ECMO) offers the possibility of survival as a bridge to recovery, surgery, implantable left ventricular assist device (LVAD) or transplantation. V-A ECMO has been beneficial in patients with acute myocardial infarction with cardiogenic shock [3,4], postcardiotomy shock [5,6], fulminant myocarditis [7,8], refractory ventricular arrhythmias [9,10], massive pulmonary embolism with right heart failure [11], right heart failure after LVAD implantation [12] and primary allograft failure [13,14]. Vascular access for V-A ECMO is achieved by central thoracic vessel cannulation or extrathoracic peripheral cannulation of the femoral and/or axillary vessels.…”

Section: Introductionmentioning

confidence: 99%

Peripheral Venoarterial Extracorporeal Membrane Oxygenation in Combination with Intra-Aortic Balloon Counterpulsation in Patients with Cardiovascular Compromise

et al. 2014

View full text Add to dashboard Cite

Objectives: Patients with profound cardiovascular compromise have poor prognosis despite inotropic and intra-aortic balloon pump (IABP) support. Peripheral venoarterial extracorporeal membrane oxygenation (V-A ECMO) offers these patients temporary support as a bridge to various options including the ‘bridge to recovery'. Methods: We studied the outcomes of 135 patients who underwent peripheral V-A ECMO and concomitant IABP implantation in our hospital from 2007 to 2012 for various clinical indications. The ECMO circuit consisted of a centrifugal pump and an oxygenator. Results: V-A ECMO was implanted in the cardiac catheterization laboratory in 51 patients (37.8%), at the bedside in 5 (3.7%) and in the operating room in 79 (58.5%). Mean duration of support was 8.5 ± 7.1 days. Median length of stay was 28 days (interquartile range 14-62). Complications included bleeding at the access site in 14.1%, stroke in 11.1% and vascular complications requiring intervention in 16.3%. Overall inhospital survival was 57.8% with outcomes including heart transplantation (3%), implantable left ventricular assist device (8.1% as bridge to transplantation and 6.7% as destination therapy), surgery (7.4%) and myocardial recovery (40.7%). Prior IABP use and axillary cannulation were independent predictors of reduced inhospital mortality, stroke or vascular injury. Conclusions: Peripheral V-A ECMO with IABP is an effective therapy for patients with severely compromised cardiovascular function. It offers reasonable survival and a spectrum of definitive options from ‘bridge to recovery' to heart transplantation for the management of this critically ill population.

show abstract

“…In one study involving 45 patients with refractory cardiogenic shock, ECMO was associated with survival to hospital discharge in 29% (13/45) versus the expected total absence of survival without ECMO [40]. In another series, survival was achieved in 71% of patients with refractory cardiogenic failure during severe septic shock [41].…”

Section: Two Types Of Ecmo Have Been Developed: Veno-arterial Extracomentioning

confidence: 99%

“…Supporting data are case series from multiple countries [36][37][38][39][40][41]. In one study involving 45 patients with refractory cardiogenic shock, ECMO was associated with survival to hospital discharge in 29% (13/45) versus the expected total absence of survival without ECMO [40].…”

Section: Two Types Of Ecmo Have Been Developed: Veno-arterial Extracomentioning

confidence: 99%

Role of New Therapies in Reducing Mortality and Major Morbidity in Patients with Systolic Heart Failure

Yurevich¹,

Borer²

2017

The Role of the Clinical Cardiac Electrophysiologist in the Management of Congestive Heart Failure

View full text Add to dashboard Cite

Though heart failure therapies, particularly for systolic heart failure, have developed rapidly and markedly during the past four decades, a need for additional relief persists and is progressively being met. Two new drugs have been approved for marketing in the United States within the past two years, and two other glucose lowering therapies for diabetes appear to have efficacy for heart failure as well. In addition, device therapy for heart failure has progressed markedly during the past 5 years, particularly in refinements of the indications and applications of devices to minimize symptoms and hospitalizations and to maximize survival. This chapter will outline these recent developments.

show abstract

Venoarterial extracorporeal membrane oxygenation for treatment of cardiogenic shock: Clinical experiences in 45 adult patients

Cited by 182 publications

References 13 publications

The Impact of Vascular Complications on Survival of Patients on Venoarterial Extracorporeal Membrane Oxygenation

The Impact of Vascular Complications on Survival of Patients on Venoarterial Extracorporeal Membrane Oxygenation

Peripheral Venoarterial Extracorporeal Membrane Oxygenation in Combination with Intra-Aortic Balloon Counterpulsation in Patients with Cardiovascular Compromise

Role of New Therapies in Reducing Mortality and Major Morbidity in Patients with Systolic Heart Failure

Contact Info

Product

Resources

About